SCHEMBL4899475

SCHEMBL4899475

CC(C)=CCC/C(C)=C/COc1cccc(O)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 9/20 0.54
TDP1 Q9NUW8 2/20 0.54
KDM4E B2RXH2 1/20 0.54
NDUFS8 O00217 1/20 0.54
COXFA4 O00483 1/20 0.54
NDUFAB1 O14561 1/20 0.54
NDUFA1 O15239 1/20 0.54
NDUFS4 O43181 1/20 0.54
NDUFB5 O43674 1/20 0.54
NDUFB3 O43676 1/20 0.54
NDUFC1 O43677 1/20 0.54
NDUFA2 O43678 1/20 0.54
NDUFS5 O43920 1/20 0.54
NDUFS7 O75251 1/20 0.54
NDUFS2 O75306 1/20 0.54
NDUFS6 O75380 1/20 0.54
NDUFB1 O75438 1/20 0.54
NDUFS3 O75489 1/20 0.54
NDUFB6 O95139 1/20 0.54
NDUFA3 O95167 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4899481 1.00 ALOX15 (0.54) ALOX15TDP1KDM4ENDUFS8COXFA4
SCHEMBL27662550 0.99 ALOX15 (0.55) ALOX15TDP1KDM4ENDUFS8COXFA4
SCHEMBL24183240 0.99 ALOX15 (0.55) ALOX15TDP1KDM4ENDUFS8COXFA4
SCHEMBL24183231 0.90 ALOX15 (0.60) ALOX15TDP1KDM4ENDUFS8COXFA4
SCHEMBL24183242 0.84 ALOX15 (0.53) ALOX15TDP1KDM4ENDUFS8COXFA4
SCHEMBL7536951 0.83 TRPV1 (0.56) ALOX15TDP1KDM4ENDUFS8COXFA4
SCHEMBL11757158 0.83 TRPV1 (0.56) ALOX15TDP1KDM4ENDUFS8COXFA4
SCHEMBL25231921 0.82 ALOX15 (0.53) ALOX15TDP1KDM4ENDUFS8COXFA4
SCHEMBL29799204 0.82 ALOX15 (0.53) ALOX15TDP1KDM4ENDUFS8COXFA4
SCHEMBL11762159 0.82 ALOX15 (0.55) ALOX15TDP1KDM4ENDUFS8COXFA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10201510-B2 Compositions and methods for treatment of neurological symptoms associated with alcohol-withdrawal and for convulsive seizure OREGON HEALTH & SCIENCE UNIVERSITY (US) 2019-02-12 US claimed
US-20080286209-A1 Compositions and Methods for Treatment of Neurological Symptoms Associated with Alcohol-Withdrawal and for Consulsive Seizure OREGON HEALTH & SCIENCE UNIVERSITY (US) 2008-11-20 US claimed
WO-2006086372-A2 COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROLOGICAL SYMPTOMS ASSOCIATED WITH ALCOHOL-WITHDRAWAL AND FOR CONVULSIVE SEIZURE OREGON HEALTH & SCIENCE UNIVERSITY (US) 2006-08-17 WO claimed
US-10201510-B2 Compositions and methods for treatment of neurological symptoms associated with alcohol-withdrawal and for convulsive seizure OREGON HEALTH & SCIENCE UNIVERSITY (US) 2019-02-12 US disclosed
US-10201510-B2 Compositions and methods for treatment of neurological symptoms associated with alcohol-withdrawal and for convulsive seizure OREGON HEALTH & SCIENCE UNIVERSITY (US) 2019-02-12 US disclosed
US-20080286209-A1 Compositions and Methods for Treatment of Neurological Symptoms Associated with Alcohol-Withdrawal and for Consulsive Seizure OREGON HEALTH & SCIENCE UNIVERSITY (US) 2008-11-20 US disclosed
US-20080286209-A1 Compositions and Methods for Treatment of Neurological Symptoms Associated with Alcohol-Withdrawal and for Consulsive Seizure OREGON HEALTH & SCIENCE UNIVERSITY (US) 2008-11-20 US disclosed
US-20080286209-A1 Compositions and Methods for Treatment of Neurological Symptoms Associated with Alcohol-Withdrawal and for Consulsive Seizure OREGON HEALTH & SCIENCE UNIVERSITY (US) 2008-11-20 US disclosed
US-20080286209-A1 Compositions and Methods for Treatment of Neurological Symptoms Associated with Alcohol-Withdrawal and for Consulsive Seizure OREGON HEALTH & SCIENCE UNIVERSITY (US) 2008-11-20 US disclosed
WO-2006086372-A3 COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROLOGICAL SYMPTOMS ASSOCIATED WITH ALCOHOL-WITHDRAWAL AND FOR CONVULSIVE SEIZURE UNIV OREGON HEALTH & SCIENCE (US) 2007-04-19 WO disclosed
WO-2006086372-A2 COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROLOGICAL SYMPTOMS ASSOCIATED WITH ALCOHOL-WITHDRAWAL AND FOR CONVULSIVE SEIZURE OREGON HEALTH & SCIENCE UNIVERSITY (US) 2006-08-17 WO disclosed
WO-2006086372-A2 COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROLOGICAL SYMPTOMS ASSOCIATED WITH ALCOHOL-WITHDRAWAL AND FOR CONVULSIVE SEIZURE OREGON HEALTH & SCIENCE UNIVERSITY (US) 2006-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10201510-B2 Compositions and methods for treatment of neurological symptoms associated with alcohol-withdrawal and for convulsive seizure ADH1C, ADH1A, CHRNA10 ALOX15 632/4885TDP1 1254/4885KDM4E 2450/4885
US-20080286209-A1 Compositions and Methods for Treatment of Neurological Symptoms Associated with Alcohol-Withdrawal and for Consulsive Seizure PNMT, ADH1A, CHRNA10 ALOX15 1764/4885TDP1 1136/4885KDM4E 2531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.